The CDMO has been identified as best-in-class CDMO in global biopharmaceutical aseptic fill-and-finish services for a third time
CDMO Vetter has been awarded the Frost & Sullivan’s 2023 Global Customer Value Leadership Award in the aseptic fill-and-finish market for the company’s high performance for its customers.
The award, presented annually by the international growth strategy consulting firm, focuses on both business and customer impact along with industry status and trends in the market. In previous years the CDMO was awarded for their Customer Value Leadership and for their Customer Service Leadership.
Frost & Sullivan recognises the companies that offer products or services customers find superior for the overall price, performance, and quality. The firm applies a rigorous analytical process to evaluate multiple nominees for each award category before determining the final recipient. The process involves a detailed evaluation of best practices criteria across the two dimensions – business and customer – for each nominated company.
Vetter’s core service offerings include drug product development, clinical and commercial aseptic filling, device assembly and secondary packaging. The award details Vetter’s consistent and successful efforts to put the customer at the center of its operations.
We always make our best efforts to provide customers with qualities that are highlighted in this prestigious award
- Pavel Zhebrouski, Frost & Sullivan’s Best Practices Research Analyst
In response to the announcement, Frost & Sullivan’s Senior Industry Analyst Surbhi Gupta said: “Vetter offers highly specialised, state-of-the-art parenteral development and manufacturing expertise for the entire life cycle, from clinical development to commercial production and packaging. Through unwavering dedication to delivering the highest quality products and services and their exceptional knowledge and expertise, they strive to ensure their customers receive the best possible services.”
Additionally, Frost & Sullivan’s Best Practices Research Analyst Pavel Zhebrouski said: “In 2021, we recognised Vetter for its business and customer impact, and we remain impressed with the continuous innovation and sustained leadership. Vetter uniquely leverages its expertise to meet its customers’ needs, particularly the growing transition to injectables.”
Vetter MD Peter Soelkner was proud of the industry recognition: “We always make our best efforts to provide customers with qualities that are highlighted in this prestigious award. We leverage our seven decades of experience and over 6,000 employees to do so.”
MD fellow Thomas Otto said: “We graciously acknowledge that this award shows we are on the right path, and we are looking to continue this approach towards the future.”